PeptidePedia The community reference

Contract development and manufacturing organisation (revision 5)

Old revision·07:32, 9 Dec 2024·FmocFrancis

This is an old revision of this page, as it stood at 07:32, 9 Dec 2024, saved by FmocFrancis with the summary correct the transit-time figure — the source gives a median, not a maximum. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Contract development and manufacturing organisation
AbbreviationCDMO
FunctionDevelopment and manufacture to a customer specification
ConsequenceBrand and manufacturer are frequently different
Topic infobox · conventions

A contract development and manufacturing organisation (CDMO) develops processes and manufactures material to the specification of a customer who sells it under their own name. The arrangement is ordinary across the pharmaceutical and fine-chemical industries and is not in itself remarkable.[1]

Its consequence for anyone reading supplier documentation is that the organisation named on a catalogue is not necessarily the organisation that made the material. A brand may be a manufacturer, a distributor of its own contract-manufactured material, or a reseller of another's — and the documentation may not distinguish these.[2]

What a CDMO does

[edit]

Services span process development, analytical method development, scale-up, manufacture and, in some cases, fill-finish. A customer may buy any subset: a fully developed process transferred in, or a molecule and a target specification with everything else contracted out.[1]

For peptides the capability that matters is synthesis at scale with the associated preparative chromatography, since the purification step is the one that requires the largest capital equipment. A house able to synthesise but not to purify at scale is limited to crude supply, and the distinction shows up in the specification a customer can be offered rather than in any claim about capability.[3]

Quality responsibility is defined by a quality agreement between the parties. In regulated manufacture the marketing authorisation holder remains responsible for the product regardless of who made it, and the agreement allocates the practical obligations.[1]

References

  1. ^ a b c International Council for Harmonisation, Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000).
  2. ^ ISO 9001:2015, Quality management systems — Requirements.
  3. ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.